Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Study of Sintilimab in Combination With Bevacizumab Biosimilar in Patients With Potentially Resectable Intermediate HCC

Next Previous
X
Search
Trial Profile

An Exploratory Study of Sintilimab in Combination With Bevacizumab Biosimilar in Patients With Potentially Resectable Intermediate HCC

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Sintilimab (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 06 Jun 2023 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2023 Updated results (As data cut off Feb &, 2023, n=30) assessing efficacy and safety of the combination therapy as conversion therapy for potentially resectable intermediate-stage HCC presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 13 Sep 2022 Status changed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top